SCHEMBL2009505

SCHEMBL2009505

COc1ccc(-n2ncc3c(OCc4ccccc4)cccc32)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.44
PIP4K2A P48426 5/20 0.44
RXFP1 Q9HBX9 1/20 0.42
MAPT P10636 4/20 0.41
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41
HTR1A P08908 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
CYP3A4 P08684 1/20 0.40
PTGER1 P34995 1/20 0.40
CSF1R P07333 1/20 0.39
SLC2A1 P11166 1/20 0.39
SLC2A2 P11168 1/20 0.39
SLC2A3 P11169 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2009318 0.88 MAPT (0.42) MAPK14PIP4K2AMAPTTP53POLB
SCHEMBL2011809 0.83 ALDH1A1 (0.48) MAPK14RXFP1MAPTTP53POLB
SCHEMBL2006258 0.82 NR3C1 (0.41) MAPK14MAPTPOLBMRGPRX4PTGER1
SCHEMBL25678123 0.81 ALDH1A1 (0.47) MAPK14MAPTTP53POLBALDH1A1
SCHEMBL25232839 0.76 CCR1 (0.48) MAPK14
SCHEMBL30481251 0.76 CCR1 (0.48) MAPK14
SCHEMBL2007484 0.76 MAPK14 (0.41) MAPK14MAPTPOLBMRGPRX4SMN1; SMN2
SCHEMBL14085312 0.75 CYP11B1 (0.42) MAPK14RXFP1MAPTTP53MRGPRX4
SCHEMBL2007006 0.75 PIP4K2A (0.41) MAPK14PIP4K2ARXFP1MAPTMRGPRX4
SCHEMBL29509768 0.75 NR3C1 (0.46) MAPK14RHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-7960563-B2 Indazoles used to treat estrogen receptor beta mediated disorders GLAXO GROUP LIMITED (GB) 2011-06-14 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GLAXO GROUP LIMITED (GB) 2010-04-08 US disclosed
EP-2118068-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS Glaxo Group Limited (GB) 2009-11-18 EP disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed
WO-2008107455-A1 INDAZOLES USED TO TREAT ESTROGEN RECEPTOR BETA MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087502-A1 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders GPER1, ESR2, ESRRB MAPK14 3632/4885PIP4K2A 1278/4885RXFP1 1539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.